Runqing Tan, Song Zhou, Min Sun, Yu Liu, Xiumei Ni, Jin He, Gang Guo, Kaiyun Liu
{"title":"重组幽门螺杆菌疫苗抗原HpaA培养基的建模与优化。","authors":"Runqing Tan, Song Zhou, Min Sun, Yu Liu, Xiumei Ni, Jin He, Gang Guo, Kaiyun Liu","doi":"10.3389/fbioe.2024.1499940","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>H. pylori</i> (<i>Helicobacter pylori</i>) infection represents a significant global health concern, exacerbated by the emergence of drug-resistant strains resulting from conventional antibiotic treatments. Consequently, the development of vaccines with both preventive and therapeutic properties has become crucial in addressing <i>H. pylori</i> infections. The <i>H. pylori</i> adhesin protein HpaA has demonstrated strong immunogenicity across various adjuvants and dosage forms, positioning it as a key candidate antigen for recombinant subunit vaccines against <i>H. pylori</i>. Optimizing fermentation culture conditions is an effective strategy to enhance product yield and lower production costs. However, to date, there has been no systematic investigation into methods for improving the fermentation yield of HpaA. Enhancing the fermentation medium to increase HpaA yield holds significant potential for application and economic benefits in the prevention and detection of <i>H. pylori</i> infection.</p><p><strong>Methods: </strong>To achieve a stable and high-yielding <i>H. pylori</i> vaccine antigen HpaA, this study constructed recombinant <i>Escherichia coli</i> expressing HpaA. The impact of fermentation medium components on the rHpaA yield was assessed using a one-factor-at-a-time approach alongside Plackett-Burman factorial experiments. Optimal conditions were effectively identified through response surface methodology (RSM) and artificial neural network (ANN) statistical computational models. The antigenicity and immunogenicity of the purified rHpaA were validated through immunization of mice, followed by Western Blot analysis and serum IgG ELISA quantification.</p><p><strong>Results: </strong>Glucose, yeast extract, yeast peptone, NH<sub>4</sub>Cl and CaCl<sub>2</sub> all contributed to the production of rHpaA, with glucose, yeast extract, and NH<sub>4</sub>Cl demonstrating particularly significant effects. The artificial neural network linked genetic algorithm (ANN-GA) model exhibited superior predictive accuracy, achieving a rHpaA yield of 0.61 g/L, which represents a 93.2% increase compared to the initial medium. Animal immunization experiments confirmed that rHpaA possesses good antigenicity and immunogenicity.</p><p><strong>Discussion: </strong>This study pioneers the statistical optimization of culture media to enhance rHpaA production, thereby supporting its large-scale application in <i>H. pylori</i> vaccines. Additionally, it highlights the advantages of the ANN-GA approach in bioprocess optimization.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"12 ","pages":"1499940"},"PeriodicalIF":4.3000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652157/pdf/","citationCount":"0","resultStr":"{\"title\":\"Modeling and optimization of culture media for recombinant <i>Helicobacter pylori</i> vaccine antigen HpaA.\",\"authors\":\"Runqing Tan, Song Zhou, Min Sun, Yu Liu, Xiumei Ni, Jin He, Gang Guo, Kaiyun Liu\",\"doi\":\"10.3389/fbioe.2024.1499940\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong><i>H. pylori</i> (<i>Helicobacter pylori</i>) infection represents a significant global health concern, exacerbated by the emergence of drug-resistant strains resulting from conventional antibiotic treatments. Consequently, the development of vaccines with both preventive and therapeutic properties has become crucial in addressing <i>H. pylori</i> infections. The <i>H. pylori</i> adhesin protein HpaA has demonstrated strong immunogenicity across various adjuvants and dosage forms, positioning it as a key candidate antigen for recombinant subunit vaccines against <i>H. pylori</i>. Optimizing fermentation culture conditions is an effective strategy to enhance product yield and lower production costs. However, to date, there has been no systematic investigation into methods for improving the fermentation yield of HpaA. Enhancing the fermentation medium to increase HpaA yield holds significant potential for application and economic benefits in the prevention and detection of <i>H. pylori</i> infection.</p><p><strong>Methods: </strong>To achieve a stable and high-yielding <i>H. pylori</i> vaccine antigen HpaA, this study constructed recombinant <i>Escherichia coli</i> expressing HpaA. The impact of fermentation medium components on the rHpaA yield was assessed using a one-factor-at-a-time approach alongside Plackett-Burman factorial experiments. Optimal conditions were effectively identified through response surface methodology (RSM) and artificial neural network (ANN) statistical computational models. The antigenicity and immunogenicity of the purified rHpaA were validated through immunization of mice, followed by Western Blot analysis and serum IgG ELISA quantification.</p><p><strong>Results: </strong>Glucose, yeast extract, yeast peptone, NH<sub>4</sub>Cl and CaCl<sub>2</sub> all contributed to the production of rHpaA, with glucose, yeast extract, and NH<sub>4</sub>Cl demonstrating particularly significant effects. The artificial neural network linked genetic algorithm (ANN-GA) model exhibited superior predictive accuracy, achieving a rHpaA yield of 0.61 g/L, which represents a 93.2% increase compared to the initial medium. Animal immunization experiments confirmed that rHpaA possesses good antigenicity and immunogenicity.</p><p><strong>Discussion: </strong>This study pioneers the statistical optimization of culture media to enhance rHpaA production, thereby supporting its large-scale application in <i>H. pylori</i> vaccines. Additionally, it highlights the advantages of the ANN-GA approach in bioprocess optimization.</p>\",\"PeriodicalId\":12444,\"journal\":{\"name\":\"Frontiers in Bioengineering and Biotechnology\",\"volume\":\"12 \",\"pages\":\"1499940\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652157/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Bioengineering and Biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3389/fbioe.2024.1499940\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2024.1499940","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Modeling and optimization of culture media for recombinant Helicobacter pylori vaccine antigen HpaA.
Introduction: H. pylori (Helicobacter pylori) infection represents a significant global health concern, exacerbated by the emergence of drug-resistant strains resulting from conventional antibiotic treatments. Consequently, the development of vaccines with both preventive and therapeutic properties has become crucial in addressing H. pylori infections. The H. pylori adhesin protein HpaA has demonstrated strong immunogenicity across various adjuvants and dosage forms, positioning it as a key candidate antigen for recombinant subunit vaccines against H. pylori. Optimizing fermentation culture conditions is an effective strategy to enhance product yield and lower production costs. However, to date, there has been no systematic investigation into methods for improving the fermentation yield of HpaA. Enhancing the fermentation medium to increase HpaA yield holds significant potential for application and economic benefits in the prevention and detection of H. pylori infection.
Methods: To achieve a stable and high-yielding H. pylori vaccine antigen HpaA, this study constructed recombinant Escherichia coli expressing HpaA. The impact of fermentation medium components on the rHpaA yield was assessed using a one-factor-at-a-time approach alongside Plackett-Burman factorial experiments. Optimal conditions were effectively identified through response surface methodology (RSM) and artificial neural network (ANN) statistical computational models. The antigenicity and immunogenicity of the purified rHpaA were validated through immunization of mice, followed by Western Blot analysis and serum IgG ELISA quantification.
Results: Glucose, yeast extract, yeast peptone, NH4Cl and CaCl2 all contributed to the production of rHpaA, with glucose, yeast extract, and NH4Cl demonstrating particularly significant effects. The artificial neural network linked genetic algorithm (ANN-GA) model exhibited superior predictive accuracy, achieving a rHpaA yield of 0.61 g/L, which represents a 93.2% increase compared to the initial medium. Animal immunization experiments confirmed that rHpaA possesses good antigenicity and immunogenicity.
Discussion: This study pioneers the statistical optimization of culture media to enhance rHpaA production, thereby supporting its large-scale application in H. pylori vaccines. Additionally, it highlights the advantages of the ANN-GA approach in bioprocess optimization.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.